Using High-Throughput Raman to Monitor Protein
Structural Changes: The Promise for Real Time Testing in Downstream Scenarios
The market for monoclonal antibodies (MAbs) is projected to reach a value of USD 350 billion by the end of 2027. Hence, the interest in optimizing production practices is of great interest given such a substantial financial driver. One of the major target areas for optimization is downstream processing (DSP). The production and purification of MAbs particularly can be challenging as these molecules are prone to several types of post-translational modifications that may reduce their efficacy and limit their shelf life. The most prevalent modifications include glycosylation, misfolding, aggregation, oxidation, deamidation, and proteolysis. Some of these can be desirable, or even necessary, such as glycosylation. However, most of the behaviors listed are detrimental to the final product constitution.
If you would like to discuss your application and are considering adopting spectroscopy as a process analytic technology, please contact us at email@example.com.